COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE
Find A Clinical Trial
Disease Type: Breast
Trial ID
20284
Sponsor ID
Seattle Genetics, Inc.
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)
Principal Investigator
Anne Favret, MD
1 Location
Trial ID
19049
Sponsor ID
Genentech, Inc.
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this…
Principal Investigator
Anne Favret, MD
5 Locations
Trial ID
19058
Sponsor ID
CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID
19054
Sponsor ID
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)
Principal Investigator
Christina Brzezniak, DO
5 Locations
Trial ID
DS8201-A-U303
Sponsor ID
DS8201-A-U303
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS
Principal Investigator
Neelima Denduluri, MD, FASCO
1 Location
Trial ID
14059
Sponsor ID
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID
18282
Sponsor ID
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)
Principal Investigator
Christina Brzezniak, DO
5 Locations
Trial ID
DS8201-A-U301
Sponsor ID
DS8201-A-U301
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A (TRASTUZUMAB DERUXTECAN), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES, INCLUDING T-DM1
Principal Investigator
Neelima Denduluri, MD, FASCO
1 Location
Trial ID
18232
Sponsor ID
(AB928CSP0002) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies
Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID
SIDE-OUT 3
Sponsor ID
Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer
Principal Investigator
Neelima Denduluri, MD, FASCO
6 Locations